Speaker Profile
Ph.D., Vice President and Enterprise Head of Cell & Gene Therapy, Labcorp
Biography
Maryland Franklin is Vice President and Enterprise Head of Cell and Gene Therapy (CGT) for Labcorp where she is responsible for development, alignment, and pursuit of the CGT strategic vision. Maryland joined Labcorp in 2019 through the acquisition of a preclinical oncology CRO where she established and led a group of scientists who advanced customer success through science, business, operations, and marketing collaboration. Maryland was a crucial member of the leadership team supporting the acquisition by Labcorp.Prior to moving into the CRO industry in 2014, Maryland had over 15 years experience in biotech and pharma partnering on numerous multi-disciplinary teams delivering therapeutic candidates from Research into Development including a key role in bringing four drugs into Phase 1 clinical trials.Maryland received her Ph.D. in Medical Genetics from the University of Alabama at Birmingham where she pursued research in cancer gene therapy.
Session Abstract – PMWC 2025 Silicon Valley
Track Chair: Maryland Franklin, Labcorp
- Cross-Application of Oncology Drugs in Rare Diseases
- Razelle Kurzrock, Medical College of Wisconsin
- PMWC 2025 Award Ceremony
Luminary Honoree: David R. Liu, Broad Institute & Crystal Mackal, Stanford University
Pioneer Honoree: Drew Weissman, Penn Medicine
- Breakthroughs in Cancer Immunotherapy: mRNA Vaccines and CAR T-Cell Advances (PANEL)
Chair: Ira Mellman, Medici Therapeutics
- Drew Weissman, Penn Medicine
- Crystal Mackal, Stanford University - Next-Generation ADCs: Challenges and Innovations in Immunotherapy Combinations (PANEL)
Chair: Sandhya Girish, Gilead
- Bin Liu, UCSF
- Hanspeter Gerber, Sutro Bioscience
- Amrita Kamath, Genentech
- Stephen Eck, MacroGenics - Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
- Janet Xiao, Morrison & Foerster LLP
- Keynote: Base Editing, Prime Editing, and Targeted Gene Integration: Precision Therapeutic Genome Editingn
- David R. Liu, Broad Institute
- Advances in Allogeneic Cell Therapies: Overcoming Hurdles and Expanding Applications (PANEL)
Chair: Elliot Norry, Adaptimmune
- Larry Lamb, IN8bio
- Indu Ramachandran, Century Therapeutics - Bottlenecks in Manufacturing of Cell Therapies
- Fabian Gerlinghaus, Cellares
- Transforming Cancer Treatment: Stem Cell and Gene Therapy Breakthroughs
Chair: Catriona Jamieson, UCSD Health
- Irv Weisman, Stanford
- Collaborations Advancing Genetics-based Diagnostic Testing for Cell and Gene Therapy
Chair: Maryland Franklin, Labcorp
- Data-Driven Innovations in Oncology Cell Therapy Trials
- Prabhu Snehit, Stanford
- Advancements and Future Directions in Therapeutic Ultrasound for Precision Medicine
Chair: Masha Stromme, EXACT Therapeutics
- John de Groot, UCSF
- Bhaskar Ramamurthy, Cordance Medical
- Raag Airan, Stanford
